4.5 Review

Polymyxin B versus colistin: an update

期刊

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 13, 期 12, 页码 1481-1497

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2015.1093933

关键词

colistimethate sodium; colistin sulfate; multi-drug resistance; pharmacokinetics and pharmacodynamics; polymyxin B; polymyxin combination therapy; polymyxins; polypeptide antibiotics

资金

  1. Janssen-Cilag
  2. Pfizer Inc
  3. Merck Sharp & Dohme (I.A) Corp.

向作者/读者索取更多资源

Polymyxin B and colistin (polymyxin E) are polypeptide antibiotics that were developed in the 1940s, but fell into disfavor due to their high toxicity rates. These two antibiotics were previously regarded to be largely equivalent, due to similarities in their chemical structure and spectrum of activity. In recent years, several pertinent differences, especially in terms of potency and disposition, have been revealed between polymyxin B and colistin. These differences are mainly attributed to the fact that polymyxin B is administered parenterally in its active form, while colistin is administered parenterally as an inactive pro-drug, colistimethate. In this review, we summarize the similarities and differences between polymyxin B and colistin. We also discuss the potential clinical implications of these findings, and provide our perspectives on how polymyxins should be employed to preserve their utility in this era of multi-drug resistance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据